Wetherby drug developer's antigen lateral flow test receives CE mark for use as consumer self-test

The Wetherby-based firm partnered with Medusa Healthcare to obtain regulatory approval for the AffiDX antigen test for consumer self-testing and has now received the CE mark from a European Notified Body.

Avacta has an exclusive arrangement with Medusa to commercialise the consumer self-test product globally. The antigen lateral flow self-test will be marketed by Medusa under the brand name MeduFlow.

Dr Alastair Smith, CEO of Avacta, said: "This is an extremely important step forwards in the commercialisation of the AffiDX antigen test. As the pandemic progresses, the global antigen testing market is moving away from professional use antigen tests with increasing adoption of self-test products."

The antigen lateral flow test has been developed using Avacta's proprietary Affimer platform to identify individuals with a higher viral load of the virus who are therefore more likely to infect others.

The test, which uses a nasal swab and gives a result in 20 minutes, has been independently clinically validated at the Carlos III hospital in Madrid and shown to have a sensitivity across a broad range of viral loads of 98 per cent and a specificity of 99 per cent.

The AffiDX antigen lateral flow test was CE marked for professional use in the UK and EU in June 2021.

Dr Smith said: "The AffiDX test is the first UK-developed SARS-CoV-2 antigen test that has received a CE mark for self-testing which, coupled with the fact that it is based on innovative UK technology and is manufactured in the UK are important selling points for customers in the UK, EU and elsewhere.

"Our partners at Medusa have rapidly obtained regulatory approval, and we look forward to working closely with them to provide consumers with reliable, high quality tests that address this substantial market."

---

Support The Yorkshire Post and become a subscriber today.

Your subscription will help us to continue to bring quality news to the people of Yorkshire. In return, you'll see fewer ads on site, get free access to our app and receive exclusive members-only offers.

So, please - if you can - pay for our work. Just £5 per month is the starting point. If you think that which we are trying to achieve is worth more, you can pay us what you think we are worth. By doing so, you will be investing in something that is becoming increasingly rare. Independent journalism that cares less about right and left and more about right and wrong. Journalism you can trust.

Thank you

James Mitchinson